Treatment Study for Emphysema due to Alpha1-Antitrypsin Deficiency

Medical Condition: Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency

Facility/Clinic: Accellacare

Age: 18-70

Gender: Male/Female

Description: The purpose of this research study is to determine whether a new investigational drug is safe and effective in slowing down the progression of lung damage in people with AATD. AATD causes an increased risk of chronic obstructive pulmonary disease (COPD) in the form of emphysema. This research study may be an option if you:

  • Have a diagnosis of Alpha1-Antitrypsin Deficiency
  • Are willing to receive genotyping and phenotyping tests
  • Have not received Alpha1-PI Augmentation therapy within the last 6 months

Other criteria apply. Please make sure to discuss this study with a member of our research staff to ensure this research study is a good fit for you. Qualified participants will receive all study-related care and study medication at no cost.

Enrollment: Open

Patient Commitment Duration: Approximately 3 years

Number of visits in study: Approximately 13 clinic visits

Patient Compensation: You will be provided with all study drugs, study examinations and medical tests related to the study at no cost to you. You will also be compensated for travel-related expenses and paid for each study visit.

The team at WH Research can guide interested clinical research participants through the process of enrolling in a trial.
Please call 910-362-4040 between the hours of 8am-5pm for general research questions.